ES2586805T3 - Análogos de péptidos para tratar enfermedades y trastornos - Google Patents

Análogos de péptidos para tratar enfermedades y trastornos Download PDF

Info

Publication number
ES2586805T3
ES2586805T3 ES12846423.7T ES12846423T ES2586805T3 ES 2586805 T3 ES2586805 T3 ES 2586805T3 ES 12846423 T ES12846423 T ES 12846423T ES 2586805 T3 ES2586805 T3 ES 2586805T3
Authority
ES
Spain
Prior art keywords
disorders
treat diseases
peptide analogs
peptide
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12846423.7T
Other languages
English (en)
Inventor
Nozer M. Mehta
William Stern
Amy M. Sturmer
Morten Asser Karsdal
Kim Henriksen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KeyBioscience AG
Original Assignee
KeyBioscience AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KeyBioscience AG filed Critical KeyBioscience AG
Priority claimed from PCT/US2012/063332 external-priority patent/WO2013067357A1/en
Application granted granted Critical
Publication of ES2586805T3 publication Critical patent/ES2586805T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Abstract

Un péptido AcCSNLSTCVLGKLSQELHKLQTYPRTDVGANAP-NH2 sec. con núm. de ident.: 15.
ES12846423.7T 2011-11-02 2012-11-02 Análogos de péptidos para tratar enfermedades y trastornos Active ES2586805T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161554771P 2011-11-02 2011-11-02
US201161554771P 2011-11-02
US201161578620P 2011-12-21 2011-12-21
US201161578620P 2011-12-21
PCT/US2012/063332 WO2013067357A1 (en) 2011-11-02 2012-11-02 Peptide analogs for treating diseases and disorders

Publications (1)

Publication Number Publication Date
ES2586805T3 true ES2586805T3 (es) 2016-10-19

Family

ID=51266018

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12846423.7T Active ES2586805T3 (es) 2011-11-02 2012-11-02 Análogos de péptidos para tratar enfermedades y trastornos
ES16174260.6T Active ES2673617T3 (es) 2011-11-02 2012-11-02 Miméticos de calcitonina para tratar enfermedades y trastornos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16174260.6T Active ES2673617T3 (es) 2011-11-02 2012-11-02 Miméticos de calcitonina para tratar enfermedades y trastornos

Country Status (12)

Country Link
EP (3) EP3357540A1 (es)
CY (1) CY1120332T1 (es)
DK (2) DK2773365T3 (es)
ES (2) ES2586805T3 (es)
HR (1) HRP20180903T1 (es)
HU (1) HUE039105T2 (es)
LT (1) LT3095484T (es)
PL (1) PL3095484T3 (es)
PT (1) PT3095484T (es)
RS (1) RS57519B1 (es)
SI (1) SI3095484T1 (es)
TR (1) TR201808456T4 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201704429D0 (en) * 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4764589A (en) * 1987-05-26 1988-08-16 Rorer Pharmaceutical Corporation [N-alpha-acyl,8-glycine, des-19-leucine]-calcitonin
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ES2375330T3 (es) 1997-04-16 2012-02-28 Unigene Laboratories, Inc. Expresión directa de péptidos en medios de cultivo.
EP1137431A1 (en) 1998-12-04 2001-10-04 Provalis UK Limited Pharmaceutical compositions containing insulin
CA2369591C (en) 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
CA2520660C (en) 2003-03-28 2013-08-20 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
NZ544645A (en) 2003-07-23 2009-04-30 Novartis Ag Use of calcitonin in osteoarthritis
US20070172517A1 (en) 2003-09-17 2007-07-26 Ben-Sasson Shmuel A Compositions capable of facilitation penetration across a biological barrier
AU2005263729B2 (en) 2004-07-22 2011-01-06 Bey Pharma GmbH Use of compounds containing thiol groups as an efflux pump inhibitor
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
ES2437068T3 (es) 2005-06-24 2014-01-08 Enteris Biopharma, Inc. Líneas celulares para expresar enzima útil en la preparación de productos amidados
ES2462117T3 (es) 2005-09-06 2014-05-22 Oramed Pharmaceuticals Inc. Métodos y composiciones para la administración oral de proteínas
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
DK1834635T3 (da) 2006-03-13 2011-10-24 Advancell Advanced In Vitro Cell Technologies S A Stabile nanokapselsystemer til administrtion af aktive molekyler
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
CN102292346B (zh) * 2009-01-22 2015-12-02 关键生物科学有限公司 肥胖的治疗
BRPI1009392A2 (pt) * 2009-03-12 2016-03-08 Nordic Bioscience As "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."

Also Published As

Publication number Publication date
HRP20180903T1 (hr) 2018-08-24
CY1120332T1 (el) 2019-07-10
DK3095484T3 (en) 2018-06-25
RS57519B1 (sr) 2018-10-31
PL3095484T3 (pl) 2018-10-31
HUE039105T2 (hu) 2018-12-28
EP3095484A1 (en) 2016-11-23
TR201808456T4 (tr) 2018-07-23
PT3095484T (pt) 2018-06-20
EP2773365B1 (en) 2016-07-20
ES2673617T3 (es) 2018-06-25
DK2773365T3 (en) 2016-08-29
EP3357540A1 (en) 2018-08-08
EP2773365A1 (en) 2014-09-10
EP3095484B1 (en) 2018-05-02
SI3095484T1 (en) 2018-08-31
EP2773365A4 (en) 2015-05-20
LT3095484T (lt) 2018-08-10

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
UY34347A (es) Proteínas de función dual para tratar trastornos metabólicos
ECSP14013153A (es) Compuestos inhibidores de metaloenzimas
UY34346A (es) Proteínas de fusión para tratar trastornos metabólicos
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
EA201691582A1 (ru) Новые фармацевтические препараты
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
ECSP14013152A (es) Compuestos inhibidores de metaloenzimas
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
CY1120219T1 (el) Ανταγωνιστες της il17c για τη θεραπευτικη αντιμετωπιση φλεγμονωδων διαταραχων
AR089993A1 (es) Macrociclos peptidomimeticos
TR201901886T4 (tr) DNA-PK inhibitörleri.
MY178142A (en) Anti-phf-tau antibodies and their uses
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
UY34406A (es) Compuestos y métodos para mejorar la respuesta inmune innata
CR20140342A (es) Composiciones y métodos para el tratamiento de enfermedades y trastornos hepáticos
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.